Money
Filter News
Found 84,833 articles
-
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly.
-
On the heels of a late-stage victory for its antipsychotic drug Caplyta in patients with major depressive disorder, Intra-Cellular Therapies is now offering 6.8 million shares at $73 a piece.
-
Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
4/18/2024
Intra-Cellular Therapies, Inc. announced the pricing of its previously announced underwritten public offering of 6,849,316 shares of its common stock at a public offering price of $73.00 per share.
-
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
4/18/2024
Zura Bio Limited today announced that it has entered into subscription agreements for a private placement that is expected to result in gross proceeds of approximately $112.5 million, before deducting placement agent fees and offering expenses (the “Private Placement”).
-
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
4/18/2024
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
-
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
4/18/2024
TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).
-
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
4/18/2024
Biohaven Ltd. announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share.
-
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic
4/18/2024
Pathios Therapeutics Limited ("Pathios"), a biotech company focused on the development of first-in-class therapies for cancer, today announced that the company has raised $25 million in the first close of a Series B financing. The financing consists of a new strategic investment from Bristol Myers Squibb, as well as support from existing investors including Canaan and Brandon Capital.
-
Interim report Q1, 2024: Strong growth in APAC and solid margins
4/18/2024
Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.
-
Hansa Biopharma interim report January-March 2024
4/18/2024
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and year-end report for January to March 2024.
-
As its lead oral targeted protein degrader moves through Phase III in partnership with Pfizer, Arvinas signs a licensing deal handing over all rights and responsibilities to Novartis.
-
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
-
On the heels of a Phase IIb win, Arrowhead Pharmaceuticals’ plozasiran could fulfill a critical unmet need in dyslipidemia treatment bringing in $707 million in sales by 2032, according to data analytics firm GlobalData.
-
The Menlo Park, Calif.-based venture capital firm has raised more than $1 billion since last year, with this latest injection of capital going to its biopharma investment funds.
-
BAP Pharma Announces Grand Opening Ceremony for New US Headquarters in Somerset, NJ
4/17/2024
BAP Pharma will welcome guests and dignitaries to the Grand Opening Ceremony of its new headquarters on Randolph Road with a formal ribbon cutting ceremony, speeches, and exclusive tours of the new facility.
-
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
4/17/2024
Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.
-
Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams
4/17/2024
Asieris Pharmaceuticals released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization.
-
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
4/17/2024
NANOBIOTIX announced that it will report its financial and operational results for the fourth quarter and full year ended December 31, 2023, on Wednesday, April 24, 2024, after the close of the US market.
-
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock - April 17, 2024
4/17/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
-
Biohaven Announces Proposed Public Offering of Common Shares - April 17, 2024
4/17/2024
Biohaven Ltd. announced that it has commenced an underwritten public offering of $200 million of its common shares.